JANUMET

Type: Product
Name: JANUMET
First reported Oct 28 2014 - Updated Oct 29 2014 - 1 reports

Merck Can Still Offer Healthy Doses Of Profits, Despite Disappointing Results

Summary Merck is still making money, despite the revenue miss. With a yield of 3.10% and having just been granted approval for a key drug by the FDA, now is the wrong time to lose faith. The best play here is to add to an existing long position and ... [Published Seeking Alpha - Oct 28 2014]
First reported Oct 27 2014 - Updated Oct 28 2014 - 1 reports

Merck bogged down by slumping sales, but cuts deliver on profits

It has been a roller-coaster ride of a year for Merck ($MRK), complete with M&A and corporate bloodletting intended to swing the company's numbers northward. Part of the drugmaker's turnaround plan could be paying off, as cost cuts delivered third-quarter ... [Published FiercePharma - Oct 27 2014]
First reported Oct 27 2014 - Updated Oct 28 2014 - 2 reports

Merck & Co., Inc. Earnings: Patent Losses and Competition Weigh on Sales

Big pharma giant Merck ( NYSE: MRK     ) hasn't been shy about the fact that it's in the midst of a multi-year turnaround strategy focused on generating organic and acquired growth, but shareholders sometimes need a reminder that there could be bumps ... [Published Motley Fool Discussion Boards - Oct 27 2014]
First reported Oct 27 2014 - Updated Oct 27 2014 - 1 reports

Merck Tops on Q3 Earnings, Patent Expiries Hit Revenues

Merck & Co. ( MRK - Analyst Report ) reported third quarter 2014 earnings of 90 cents per share, beating the Zacks Consensus Estimate of 88 cents. Earnings, however, declined 2.2% from the year-ago period.Revenues for the quarter declined 4.3% to $10.557 ... [Published Zacks.com - Oct 27 2014]
First reported Oct 27 2014 - Updated Oct 27 2014 - 1 reports

Merck & Co., Inc. Tops Earnings, Misses Revenue Estimates

Shares of Merck & Co. were little moved in premarket trading as of this writingMerck & Co., Inc.  ( NYSE:MKR ) released the earnings results from its third quarter this morning before opening bell, posting adjusted earnings of 90 cents per share on $10.56 ... [Published Value Walk - Oct 27 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Type 2 - At what Glucose reading should you head to the ER?

My blood glucose reading had been very normal for an extended period of time. So much so, that I had stopped testing and gotten lax on my diet. (Not too smart, I know)Friday my fasting reading was 460. Through the day it improved some, but stayed upwards ... [Published HealthBoards - Sep 29 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Merck & Co posts net profit of $2,004 million in Q2

Merck & Co has registered strong growth in profits during the second quarter ended June 2014 despite lower sales. Its net profit increased by 121 per cent to $2,004 million from $906 million in the corresponding period of last year. However, its net sales ... [Published PharmaBiz - Aug 05 2014]

Quotes

CEO Kenneth Frazier was pleased with his company's performance, however, saying "We delivered solid third-quarter results and are making steady progress in our transformation, including divesting non-core assets, reducing our expense base and investing in our promising new product launches and pipeline."
"Last October, we launched a multi-year initiative to transform Merck and build a platform for sustained, future growth" said chief executive Kenneth Frazier, noting that “one year later, we delivered solid third-quarter results and are making steady progress in our tr...
A MSD spokesperson said, "MSD is extremely disappointed with the decision of denial of injunction by the Delhi High Court against Glenmark for patent violation of our drugs Januvia and Janumet.$ MSD is considering all options, including an appeal of the decision." Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate

More Content

All (14) | News (13) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Merck Can Still Offer Healthy Doses Of Profits,... [Published Seeking Alpha - Oct 28 2014]
Merck & Co., Inc. Earnings: Patent Losses and C... [Published Motley Fool Discussion Boards - Oct 27 2014]
Merck & Co third-qtr disappoints, as earnings p... [Published Pharma Letter - Oct 27 2014]
'Breakthrough' for Merck's Keytruda as firm pos... [Published Pharma Times - Oct 27 2014]
Merck bogged down by slumping sales, but cuts d... [Published FiercePharma - Oct 27 2014]
Merck Tops on Q3 Earnings, Patent Expiries Hit ... [Published Zacks.com - Oct 27 2014]
Merck & Co., Inc. Tops Earnings, Misses Revenue... [Published Value Walk - Oct 27 2014]
Type 2 - At what Glucose reading should you hea... [Published HealthBoards - Sep 29 2014]
Merck & Co posts net profit of $2,004 million i... [Published PharmaBiz - Aug 05 2014]
Merck & Co net earnings moves up by 7% in Q1 [Published PharmaBiz - Apr 30 2014]
Januvia Pancreatic Cancer Allegations Help: Res... [Published PRWeb - Feb 27 2014]
Januvia Pancreatic Cancer Allegations Alert: Re... [Published PRWeb - Jan 19 2014]
TrialNetworks Welcomes Global Pharmaceutical In... [Published PRWeb - Jan 16 2014]
Delhi High Court not to grant interim relief to... [Published Topnews.in - Apr 05 2013]
1
In Focus
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Type 2 - At what Glucose reading should you hea... [Published HealthBoards - Sep 29 2014]
My blood glucose reading had been very normal for an extended period of time. So much so, that I had stopped testing and gotten lax on my diet. (Not too smart, I know)Friday my fasting reading was 460. Through the day it improved some, but stayed upwards ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.